BMA-BAP1-MUT-RCC-PROGNOSTIC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BAP1-MUT-RCC-PROGNOSTIC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-05-05 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-RCC |
| Sources | SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Actionability Facts
| Biomarker | BIO-BAP1-MUTATION |
|---|---|
| Variant | BAP1 loss-of-function mutation (somatic; ~15-20% sporadic ccRCC); IHC loss of nuclear BAP1 staining is a validated tissue surrogate |
| Disease | DIS-RCC |
| ESCAT tier | IIIA |
Notes
BAP1 mutation identifies poor-prognosis ccRCC. Relevant for counselling and potentially for intensity of treatment (supports aggressive treatment approach in fit patients). No biomarker-directed therapy approved. PBRM1 (mutually exclusive) is separately prognostic with better outcomes. Both are complementary to IMDC clinical risk score. Germline BAP1 testing indicated if personal/family history of mesothelioma, uveal melanoma, or other BAP1-associated tumours.
Used By
No reverse references found in the YAML corpus.